The following transcript has been edited for clarity:

Hi, welcome to the Retinal Physician channel. I’m Diana V. Do, MD, and today at the American Academy of Ophthalmology retina subspecialty day, I had the pleasure of presenting some real-world analysis of aflibercept 8 mg (Eylea HD; Regeneron) using the IRIS registry database.

We looked at patients who were treatment-naïve, or they had prior treatment with aflibercept 2 mg (Eylea; Regeneron) and then were switched to aflibercept 8 mg. In our study, we followed these patients for up to one year and we looked at their injection intervals and their visual acuity. In the treatment-naïve eyes, we used over 3,000 wet age-related macular degeneration (AMD) eyes and over 400 diabetic macular edema (DME) eyes. In the treatment-experienced patients, we used over 8,000 wet AMD eyes and over 2,000 DME eyes.

What were our results? We found that in the treatment-naïve subjects, they were able to achieve an injection interval of 12 weeks after the initial 6 months. In addition, they gained 4 letters of vision in the AMD population and 5 letters of vision in the DME population. In the treatment-experienced patients who were switched over from 2 mg to 8 mg of aflibercept, we found benefit as well. These eyes were able to extend their injection interval by an additional 2 weeks and also maintain their vision. This is very exciting data from the retina subspecialty day. RP